### Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 3

ALEXION PHARMACEUTICALS INC Form 3 July 24, 2014 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

#### OMB APPROVAL

OMB 3235-0104 Number: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

Statement (Month/Day/Year) 07/16/2014	3. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]			
	Person(s) to Is	ssuer	5. If Amendment, Date Original Filed(Month/Day/Year)	
	X_ Director 10% Owne Officer Other (give title below) (specify below)		6. Individual or Joint/Group	
Table I - Non-Derivative Securities Beneficially Owned				
		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)	
ch class of securities benefici bond to the collection of ined in this form are not	51	EC 1473 (7-02	)	
	07/16/2014 <b>Table I - N</b> 2. Amount or Beneficially (Instr. 4) ch class of securities benefici bond to the collection of ined in this form are not	(Month/Day/Year) 07/16/2014 4. Relationshi Person(s) to Is (Check X Director Officer (give title below Table I - Non-Derivat 2. Amount of Securities Beneficially Owned (Instr. 4) ch class of securities beneficially Stood to the collection of	(Month/Day/Year) 07/16/2014 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <u>—X_Director</u> <u>—10% 0</u> <u>—Officer</u> <u>—0 Other</u> (give title below) (specify below) <b>Table I - Non-Derivative Securiti</b> 2. Amount of Securities 3. Beneficially Owned Ownership (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) Ch class of securities beneficially SEC 1473 (7-02) pond to the collection of ined in this form are not	

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

## Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 3

Date	Expiration	Title	Amount or	Security	Direct (D)
Exercisable	Date		Number of		or Indirect
			Shares		(I)
					(Instr. 5)

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>		Relationships				
		Director	10% Owner	Officer	Other	
COUGHLIN CHRISTOPHER J C/O ALEXION PHARMACEUTICA 352 KNOTTER DRIVE CHESHIRE, CT 06410	LS, INC.	ÂX	Â	Â	Â	
Signatures						
/s/ Michael Greco Attorney-in-Fact	07/24/2014					
<pre>**Signature of Reporting Person</pre>	Date					
Explanation of Responses:						

# No securities are beneficially owned

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.